Ganciclovir - Revision history

Aidan: /* Dosing */

2024-01-09T18:44:59Z

Dosing

← Older revision		Revision as of 18:44, 9 January 2024
Line 25:		Line 25:
	== Dosing ==		== Dosing ==

	* If non-obese (BMI <30), use total body weight; if obese (BMI ≥30), use adjusted body weight		* If non-obese (BMI <30), use total body weight; if obese (BMI ≥30), use [[adjusted body weight]]

	=== Adult Dosing ===		=== Adult Dosing ===

Aidan: /* Dosing */

2021-05-30T00:41:49Z

Dosing

← Older revision		Revision as of 00:41, 30 May 2021
Line 24:		Line 24:

	== Dosing ==		== Dosing ==

			* If non-obese (BMI <30), use total body weight; if obese (BMI ≥30), use adjusted body weight

			=== Adult Dosing ===

			* Induction dose: 5 mg/kg q12h
			* Maintenance dose: 5 mg/kg q24h or 6 mg/kg 5x/week

	=== Pediatric Dosing ===		=== Pediatric Dosing ===

Aidan: /* Safety */

2020-09-12T01:17:57Z

Safety

← Older revision		Revision as of 01:17, 12 September 2020
Line 1:		Line 1:
	== Background ==		==Background==

	*Guanosine nucleoside analogue similar to acyclovir		*Guanosine nucleoside analogue similar to acyclovir
	*Indications: {{#ask: [[Is treated by::ganciclovir]] \| default=none}}		*Indications: {{#ask: [[Is treated by::ganciclovir]] \| default=none}}

	=== Mechanism of Action ===		===Mechanism of Action===

	*Analog of deoxyguanosine, competes with deoxyguanosine to inhibit viral DNA polymerase		*Analog of deoxyguanosine, competes with deoxyguanosine to inhibit viral DNA polymerase

	=== Mechanisms of Resistance ===		===Mechanisms of Resistance===

	*Resistance in [[CMV]]		*Resistance in [[CMV]]
Line 14:		Line 14:
	**Can also develop through mutations in the target UL54 DNA polymerase		**Can also develop through mutations in the target UL54 DNA polymerase

	=== Spectrum of Activity ===		===Spectrum of Activity===

	* Active against [[HSV-1]], [[HSV-2]], [[VZV]], [[CMV]], [[HHV-6]], and [[HHV-8]]		*Active against [[HSV-1]], [[HSV-2]], [[VZV]], [[CMV]], [[HHV-6]], and [[HHV-8]]

	=== Pharmacokinetics and Pharmacodynamics ===		===Pharmacokinetics and Pharmacodynamics===

	*Oral bioavailability 6-8%		*Oral bioavailability 6-8%
			*CNS penetration 24-67% of serum levels

	== ~~Safety~~ ==		== Dosing ==

			=== Pediatric Dosing ===
⚫	* Major toxicity is cytopenias

			* Ganciclovir 5-6 mg/kg IV q12h

			==Safety==

		⚫	*Major toxicity is cytopenias
			**Usually develops in first one to two weeks of treatment
			**Contraindicated when neutrophils <0.5 cells/mL or platelets <25 cells/mL

			=== Drug-Drug Interactions ===

			* [[Zidovudine]], [[didanosine]], [[probenecid]], and [[imipenem-cilastatin]] (increases risk of seizures)

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 01:14, 12 September 2020

2020-09-12T01:14:08Z

← Older revision		Revision as of 01:14, 12 September 2020
Line 1:		Line 1:
			== Background ==
⚫	* Guanosine nucleoside analogue similar to acyclovir

	* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
		⚫	*Guanosine nucleoside analogue similar to acyclovir
		⚫	*Indications: {{#ask: [[Is treated by::ganciclovir]] \| default=none}}

			=== Mechanism of Action ===

			*Analog of deoxyguanosine, competes with deoxyguanosine to inhibit viral DNA polymerase

			=== Mechanisms of Resistance ===

		⚫	*Resistance in [[CMV]]
		⚫	**Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
		⚫	**Can also develop through mutations in the target UL54 DNA polymerase

			=== Spectrum of Activity ===

			* Active against [[HSV-1]], [[HSV-2]], [[VZV]], [[CMV]], [[HHV-6]], and [[HHV-8]]

			=== Pharmacokinetics and Pharmacodynamics ===

		⚫	*Oral bioavailability 6-8%

			== Safety ==

	* Major toxicity is cytopenias		* Major toxicity is cytopenias
⚫	* Resistance in [[CMV]]
⚫	** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
⚫	** Can also develop through mutations in the target UL54 DNA polymerase
⚫	* Oral bioavailability 6-8%
⚫	* Indications: {{#ask: [[Is treated by::ganciclovir]] \| default=none}}

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 14:08, 24 October 2019

2019-10-24T14:08:06Z

← Older revision		Revision as of 14:08, 24 October 2019
Line 1:		Line 1:
	* Guanosine nucleoside analogue similar to acyclovir		* Guanosine nucleoside analogue similar to acyclovir
	* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase		* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
			* Major toxicity is cytopenias
	* Resistance in [[CMV]]		* Resistance in [[CMV]]
	** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form		** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form

Aidan at 01:58, 24 October 2019

2019-10-24T01:58:33Z

← Older revision		Revision as of 01:58, 24 October 2019
Line 5:		Line 5:
	** Can also develop through mutations in the target UL54 DNA polymerase		** Can also develop through mutations in the target UL54 DNA polymerase
	* Oral bioavailability 6-8%		* Oral bioavailability 6-8%
			* Indications: {{#ask: [[Is treated by::ganciclovir]] \| default=none}}

	[[Category:Antivirals]]		[[Category:Antivirals]]

Aidan at 01:52, 24 October 2019

2019-10-24T01:52:50Z

← Older revision		Revision as of 01:52, 24 October 2019
Line 5:		Line 5:
	** Can also develop through mutations in the target UL54 DNA polymerase		** Can also develop through mutations in the target UL54 DNA polymerase
	* Oral bioavailability 6-8%		* Oral bioavailability 6-8%

			[[Category:Antivirals]]

Aidan at 01:52, 24 October 2019

2019-10-24T01:52:36Z

← Older revision		Revision as of 01:52, 24 October 2019
Line 1:		Line 1:
	* Guanosine nucleoside analogue similar to acyclovir		* Guanosine nucleoside analogue similar to acyclovir
	* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase		* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
			* Resistance in [[CMV]]
	* ~~Resistance~~ ~~in [[CMV]] is~~ conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form		** Most often conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
			** Can also develop through mutations in the target UL54 DNA polymerase
	* Oral bioavailability 6-8%		* Oral bioavailability 6-8%

Aidan at 01:49, 24 October 2019

2019-10-24T01:49:59Z

← Older revision		Revision as of 01:49, 24 October 2019
Line 2:		Line 2:
	* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase		* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
	* Resistance in [[CMV]] is conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form		* Resistance in [[CMV]] is conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form
			* Oral bioavailability 6-8%

Aidan: Created page with "* Guanosine nucleoside analogue similar to acyclovir * Inhibits all human herpesviruses by inhibiting DNA polymerase * Resistance in CMV is conferred by mutations of U..."

2019-10-24T01:49:29Z

Created page with "* Guanosine nucleoside analogue similar to acyclovir * Inhibits all human herpesviruses by inhibiting DNA polymerase * Resistance in CMV is conferred by mutations of U..."

New page

* Guanosine nucleoside analogue similar to acyclovir
* Inhibits all [[human herpesviruses]] by inhibiting DNA polymerase
* Resistance in [[CMV]] is conferred by mutations of UL97 kinase, which is required in order to phosphorylate ganciclovir into its active form